BioVie completes $12 million public offering on NASDAQ

BioVie Inc. (NASDAQ: BIVI, BIVIW) closed its underwritten public offering of 6 million units, raising approximately $12 million in gross proceeds before deducting underwriting discounts and expenses.

Each unit sold for $2.00 and consisted of one share of common stock and one warrant. The company also offered pre-funded units at the same price minus a $0.0001 nominal exercise price for the pre-funded warrant component.

The underwriter partially exercised its over-allotment option to purchase an additional 667,300 warrants. The warrants began trading on the NASDAQ Capital Market under the symbol "BIVIW" on August 8, 2025.

The warrants are immediately exercisable at $2.50 per share and expire five years from issuance. Pre-funded warrants are also immediately exercisable and remain valid until exercised in full.

BioVie stated it intends to use the proceeds for working capital and general corporate purposes. ThinkEquity served as the sole book-running manager for the offering.

The Securities and Exchange Commission declared the registration statement effective on August 7, 2025. BioVie is a clinical-stage company developing drug therapies for neurological disorders, neurodegenerative conditions, and liver disease.

The company's pipeline includes bezisterim for neurological conditions and BIV201 for liver cirrhosis, which has FDA Fast Track designation and Orphan drug status.

You May Also Be Interested In

• AEVEX prices public offering of 8 million shares at $27 each
• NRx Pharmaceuticals prices public offering at $3.50 per share
• Jade Biosciences announces underwritten public offering of common stock